Biomarkers in Predicting Response to Treatment in Patients With Newly Diagnosed Stage III or Stage IV Head and Neck Cancer Treated With Carboplatin, Paclitaxel, and Radiation Therapy
Stopped early
Conditions studied: Head and Neck Cancer
In brief
RATIONALE: Studying samples of tumor tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in DNA and identify biomarkers related to cancer. It may also help doctors predict how patients will respond to treatment. PURPOSE: This research study is looking at biomarkers in predicting response to treatment in patients with newly diagnosed stage III or stage IV head and neck cancer treated with carboplatin, paclitaxel, and radiation therapy.
Key facts
- Study ID
- NCT00898430
- Run by
- Vanderbilt-Ingram Cancer Center
- People needed
- 49
- Starts
- 2003-11-01
- Expected to finish
- 2011-02-01
- Last updated by the study team
- 2013-04-02
Who can join
Age: any. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Vanderbilt-Ingram Cancer Center - Cool Springs — Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center at Franklin — Nashville, Tennessee, United States
- Vanderbilt-Ingram Cancer Center — Nashville, Tennessee, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.